Furthermore, 212 of 1129 (18.8%) participants who were administered with twice-daily IDegAsp and 463 of 1929 (31.4%) participants who were administered with conventional premixed insulin experienced at least one nocturnal hypoglycemia event. This evidence concerns the gene INS and Hypoglycemia.